2. Immunology/Inflammation
  3. PD-1/PD-L1
  4. Pembrolizumab

Pembrolizumab  (Synonyms: MK-3475; Lambrolizumab)

Cat. No.: HY-P9902 Purity: 99.74%
COA
SDS
Technical Support

Pembrolizumab (MK-3475) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.

For research use only. We do not sell to patients.

CAS No. : 1374853-91-4

Size Price Stock Quantity
Free Sample (100 μg)   Apply Now  
1 mg In-stock
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 30 publication(s) in Google Scholar

Pembrolizumab Featured Recommendations:

Pembrolizumab Related Antibodies

Top Publications Citing Use of Products

    Pembrolizumab purchased from MedChemExpress. Usage Cited in: Cancer Commun (Lond). 2025 Aug;45(8):1010-1037.  [Abstract]

    Plots of tumor growth and tumor weight for each group (5 mice/group). The results showed that in mice, the combination of Pembrolizumab and Evolocumab significantly enhanced anti-tumor efficacy compared to Pembrolizumab alone (100 µg/mouse; i.p., every 7 days).

    Pembrolizumab purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2025 Jan 21;16(1):34.  [Abstract]

    Pembrolizumab (pembro) (5-10 µg/mL, 24 h). AMM16 cells were transfected with control siRNA (siRNA ctrl; left panels) or AR siRNA (siRNA AR; right panels) and treated with the indicated ICIs at 35 μg/ml. The red fluorescence from the propidium iodide (PI) and the green fluorescence from the acridin orange (AO) staining indicate dead and total cells, respectively.

    Pembrolizumab purchased from MedChemExpress. Usage Cited in: J Immunother Cancer. 2024 Aug 6;12(8):e009024.  [Abstract]

    The PD-1 expression of macrophages isolated from the subcutaneous tumor microenvironment of mice was detected by flow cytometry (n=5). The results showed that Pembrolizumab (anti-PD-1 Ab) (20 µg/mL, 24 h) reduced PD-1 expression.

    Pembrolizumab purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2021 May 9;12(5):465.  [Abstract]

    4T1 tumor-bearing mice treated with anti-PD-1 mAbs (Pembrolizumab, 10 mg/kg; i.p.; twice a week) or LY2940002 (25 mg/kg; i.p.; twice a week) were euthanized at Day21 and the tumor volume were measured. The results showed that the administration of​ anti-PD-1 mAbs (Pembrolizumab), LY294002, or their combination​ significantly inhibited tumor growth in tumor-bearing mice.

    Pembrolizumab purchased from MedChemExpress. Usage Cited in: ACS Appl Bio Mater. 2020 Oct 19;3(10):7080-7086.

    The immunofluorescence images of the tumor from the PBS- (A), random sequence- (B), anti-PD-1 antibody- (Pembrolizumab (5 mg/kg; s.c.; every other day for 16 days)) (C) and isotype antibody-treated group (D); The scale bar in the images is 50 µm.

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Pembrolizumab (MK-3475) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.

    Isotype

    Human IgG4 kappa
    Recommend Isotype Controls
    Species Reactivity

    Human
    IC50 & Target

    PDCD1/PD-1/CD279
    In Vitro

    Pembrolizumab (MK-3475) increases the secretion of cytokines IFN-γ, TNF-α and the apoptotic cell death of A549 cells[2].
    Pembrolizumab improves the αROR1-CAR T-mediated cytotoxicity, and reduces tumorigenesis in the co-cultured αROR1-CAR T and A549 cells by blocking PD-1::PD-L1 interaction in αROR1-CAR T cells[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Pembrolizumab Related Antibodies

    Cell Cytotoxicity Assay[2]

    Cell Line: αROR1-CAR T and A549 cells
    Concentration: 10 μg/mL
    Incubation Time: Adding Pembrolizumab after A549-Red-Fluc cells preconditioned in elevated pressure (+ 100 mmHg) for 7 days.
    Result: Enhanced αROR1-CAR T killing of A549 lung cancer cells under elevated pressure.

    Apoptosis Analysis[2]

    Cell Line: A549 cells
    Concentration: 10 μg/mL
    Incubation Time:
    Result: Increased the apoptotic cell death in A549 cells, and improve the αROR1-CAR T-mediated cytotoxicity.
    In Vivo

    Pembrolizumab inhibits tumor size in A549 xenograft mice pretreated by pressure[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Six-week-old male BALB/c athymic nude mice[2]
    Dosage: 5 mg/kg
    Administration: Pembrolizumab (5 mg/kg; Intravenous injection; Once)
    Result: Reduced tumorigenesis in αROR1-CAR T cells and co-cultured with A549 cells.
    Clinical Trial
    Gene ID

    5133  [NCBI]

    Accession
    Application

    ELISA, FACS, Functional assay
    Conjugated

    Unconjugated
    Reconsititution

    The product can be reconstituted/diluted with sterile PBS or saline.
    Molecular Weight

    145.24 kDa

    CAS No.
    Appearance

    Liquid

    Color

    Colorless to light yellow

    SMILES

    [Pembrolizumab]
    Shipping

    Shipping with dry ice.
    Formulation

    Please refer to the lot-specific COA for specific buffer information.
    Storage

    Please store the product under the recommended conditions in the Certificate of Analysis.
    Format
    • Human IgG4 kappa
    Biological Activity
    • Flow cytometry analysis of PD-1 overexpression HEK293 cells labelling PD-1 with Pembrolizumab at 67nM (Red). Goat anti human IgG Fc(Alexa Fluor488) was used as the secondary antibody at 1/400 dilution. Isotype control - human IgG (Blue). Unlabeled control - Unlabelled cells (Gray).
    • Loaded Pembrolizumab on AHC2 biosensor, can bind PD-1 Protein, Human (143a.a, HEK293, His, HY-P7396) with an affinity constant of 1.898E-09 M as determined in BLI assay.
    • Immobilized PD-1 Protein, Human can bind Pembrolizumab. The EC50 for this effect is 1.8 ng/mL.
    Purity & Documentation

    Purity: 99.74%

    SDS (418 KB)

    COA (232 KB) SDS-PAGE (95 KB) SEC-HPLC (72 KB)

    Inhibitory Antibodies User Guide (603 KB)
    References
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Pembrolizumab Related Classifications

    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass   Concentration   Volume   Molecular Weight *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
    × = ×
    C1   V1   C2   V2
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Pembrolizumab1374853-91-4MK-3475 LambrolizumabMK3475MK 3475PD-1/PD-L1PD-1/Programmed death-ligand 1PD-1 inhibitorIgG4 antibody cancerimmunologyInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Pembrolizumab
    Cat. No.:
    HY-P9902
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (418 KB) Français - FR (418 KB) Deutsch - DE (418 KB) Norwegian - NO (418 KB) Español - ES (418 KB) Swedish - SV (418 KB) Italian - IT (418 KB) Korean - KR (418 KB) Portuguese - PT (418 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.